Chemometec As Stock Current Valuation
| CHEMM Stock | DKK 473.60 6.40 1.33% |
Valuation analysis of ChemoMetec AS helps investors to measure ChemoMetec's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that ChemoMetec's price fluctuation is very steady at this time. Calculation of the real value of ChemoMetec AS is based on 3 months time horizon. Increasing ChemoMetec's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since ChemoMetec is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ChemoMetec Stock. However, ChemoMetec's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 473.6 | Real 379.13 | Hype 473.6 | Naive 492.53 |
The real value of ChemoMetec Stock, also known as its intrinsic value, is the underlying worth of ChemoMetec AS Company, which is reflected in its stock price. It is based on ChemoMetec's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of ChemoMetec's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of ChemoMetec AS helps investors to forecast how ChemoMetec stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ChemoMetec more accurately as focusing exclusively on ChemoMetec's fundamentals will not take into account other important factors: ChemoMetec AS Company Current Valuation Analysis
ChemoMetec's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current ChemoMetec Current Valuation | 14.38 B |
Most of ChemoMetec's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ChemoMetec AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, ChemoMetec AS has a Current Valuation of 14.38 B. This is 25.54% lower than that of the Life Sciences Tools & Services sector and 163.17% higher than that of the Health Care industry. The current valuation for all Denmark stocks is 13.49% higher than that of the company.
ChemoMetec Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ChemoMetec's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ChemoMetec could also be used in its relative valuation, which is a method of valuing ChemoMetec by comparing valuation metrics of similar companies.ChemoMetec is currently under evaluation in current valuation category among its peers.
ChemoMetec Fundamentals
| Return On Equity | 0.49 | |||
| Return On Asset | 0.31 | |||
| Profit Margin | 0.39 % | |||
| Operating Margin | 0.50 % | |||
| Current Valuation | 14.38 B | |||
| Shares Outstanding | 17.4 M | |||
| Shares Owned By Insiders | 10.87 % | |||
| Shares Owned By Institutions | 51.35 % | |||
| Price To Earning | 197.96 X | |||
| Price To Book | 40.83 X | |||
| Price To Sales | 32.10 X | |||
| Revenue | 428.39 M | |||
| Gross Profit | 384.25 M | |||
| EBITDA | 224.86 M | |||
| Net Income | 159.47 M | |||
| Cash And Equivalents | 209.02 M | |||
| Cash Per Share | 12.01 X | |||
| Total Debt | 6.79 M | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 2.57 X | |||
| Book Value Per Share | 26.27 X | |||
| Cash Flow From Operations | 176.86 M | |||
| Earnings Per Share | 10.15 X | |||
| Target Price | 1000.0 | |||
| Number Of Employees | 162 | |||
| Beta | 1.37 | |||
| Market Capitalization | 8.48 B | |||
| Total Asset | 501.27 M | |||
| Retained Earnings | 36 M | |||
| Working Capital | 25 M | |||
| Current Asset | 33 M | |||
| Current Liabilities | 8 M | |||
| Annual Yield | 0 % | |||
| Net Asset | 501.27 M |
About ChemoMetec Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ChemoMetec AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ChemoMetec using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ChemoMetec AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with ChemoMetec
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ChemoMetec position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ChemoMetec will appreciate offsetting losses from the drop in the long position's value.Moving against ChemoMetec Stock
| 0.54 | CARL-B | Carlsberg AS | PairCorr |
| 0.53 | CARL-A | Carlsberg AS | PairCorr |
| 0.49 | JYSK | Jyske Bank AS | PairCorr |
| 0.45 | ORSTED | Orsted AS | PairCorr |
| 0.36 | GMAB | Genmab AS | PairCorr |
The ability to find closely correlated positions to ChemoMetec could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ChemoMetec when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ChemoMetec - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ChemoMetec AS to buy it.
The correlation of ChemoMetec is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ChemoMetec moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ChemoMetec AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ChemoMetec can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in ChemoMetec Stock
ChemoMetec financial ratios help investors to determine whether ChemoMetec Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ChemoMetec with respect to the benefits of owning ChemoMetec security.